Congestive Heart Failure Market Infographic
Congestive Heart Failure Market

Congestive Heart Failure (also called heart failure) is a severe condition in which the heart does not pump blood efficiently. Some of the key Congestive Heart Failure symptoms include shortness of breath, fatigue, and weakness, rapid or irregular heartbeat, reduced ability to exercise, persistent cough or wheezing, swelling of the abdomen, rapid weight gain, nausea & lack of appetite, difficulty concentrating, or decreased alertness, and chest pain, and swelling in the legs, ankles, and feet. The most common cause is lowering of the left ventricular myocardial utility along with the dysfunction of pericardium, myocardium, endocardium, heart valves, or large vessels alone or in the combination


Congestive Heart Failure Epidemiology Segmentation in the 7MM for the Study Period 2018-30


  • Total Prevalent Population of Heart Failure
  • Diagnosed Prevalent Population of Heart Failure
  • Gender-Specific Diagnosed Prevalent Cases of Heart Failure
  • Age-Specific Diagnosed Prevalent Cases of Heart Failure
  • NYHA Class-Specific Diagnosed Prevalent Cases of Heart Failure
  • Type-Specific Diagnosed Prevalent Cases of Heart Failure
  • Diagnosed Prevalent Cases of Heart Failure with Ejection Fraction
  • Diagnosed Prevalent Cases of Heart Failure Associated with Comorbidities


Congestive Heart Failure Epidemiology Insights Observed in 2020


  • The total prevalent cases of Heart Failure in the US was found to be 6,453,898. 
  • In the US, the gender-specific cases of Heart Failure in males were observed to be 2,478,297, whereas in females it was found to be 2,684,822.
  • The total prevalent cases of Heart Failure in Germany was found to be 2,955,330.
  • The total prevalent cases of Heart Failure in Japan was estimated to be 1,178,678. 


Congestive Heart Failure Market Insights


Congestive Heart Failure market size in the 7MM was found to be USD 5,955 million in 2020.


Congestive Heart Failure Market Drivers


  • Robust emerging pipeline
  • Recent approval of therapies & promising emerging therapies
  • Evidence-based therapies
  • Aging of the population
  • Rising prevalence of the disease


Congestive Heart Failure Market Barriers


  • Availability of generic and off-label therapies in the market setting
  • Lack of confidence in diagnosis and management
  • Treatment failure to stimulate and follow society’s goals and requirements


Congestive Heart Failure Emerging Therapies


The emerging drugs in the Congestive Heart Failure market are


  • OPC-61815
  • Omecamtiv Mecarbil
  • AZD4831
  • Rexlemestrocel-L (Revascor)
  • Finerenone (Kerendia)
  • Semaglutide 2.4 mg
  • Furoscix (furosemide injection)
  • HNO (Nitroxyl) Donor (BMS-986231)
  • Lenrispodun (ITI - 214)
  • Levosimendan
  • CardiAMPCell Therapy, and many more


Congestive Heart Failure Prominent Players


The key companies in the Congestive Heart Failure market are


  • Otsuka Pharmaceutical
  • Cytokinetics
  • AstraZeneca
  • Mesoblast
  • Bayer
  • Novo Nordisk
  • scPharmaceuticals
  • Bristol-Myers Squibb
  • Intra-Cellular Therapies
  • Tenax Therapeutics
  • BioCardia, and several others